Edition:
India

Lupin Ltd (LUPN.BO)

LUPN.BO on Bombay Stock Exchange

859.90INR
15 Dec 2017
Change (% chg)

Rs7.85 (+0.92%)
Prev Close
Rs852.05
Open
Rs858.00
Day's High
Rs868.00
Day's Low
Rs855.00
Volume
155,327
Avg. Vol
234,578
52-wk High
Rs1,572.25
52-wk Low
Rs807.00

Chart for

About

Lupin Limited is a pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The Company offers products in the cardiovascular, diabetology, asthma, pediatrics, central... (more)

Overall

Beta: -0.05
Market Cap(Mil.): Rs469,414.59
Shares Outstanding(Mil.): 451.84
Dividend: 7.50
Yield (%): 0.72

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Lupin Gets U.S. FDA Nod For Generic Contraceptive Treatment

* SAYS LUPIN RECEIVES FDA APPROVAL FOR GENERIC SAFYRAL TABLETS

14 Dec 2017

Yes Bank, IndusInd to join India's BSE Sensex index; Lupin, Cipla dropped

Indian private sector lenders Yes Bank Ltd and IndusInd Bank Ltd will join the BSE stock exchange's 30-member Sensex index, effective Dec. 18, the index provider said on Friday.

17 Nov 2017

Yes Bank, IndusInd to join India's BSE Sensex index; Lupin, Cipla dropped

Nov 17 Indian private sector lenders Yes Bank Ltd and IndusInd Bank Ltd will join the BSE stock exchange's 30-member Sensex index, effective Dec. 18, the index provider said on Friday.

17 Nov 2017

BUZZ-India's Lupin dives to near 4-yr lows on FDA warnings

** Drugmaker Lupin Ltd plunges as much as 17.8 pct to 850 rupees, its lowest since Nov. 2013

07 Nov 2017

BRIEF-Lupin launches generic Acticlate tablets in U.S.‍​

* Says co launches generic Acticlate tablets in U.S.‍​ Source text: http://bit.ly/2ypyZzY Further company coverage:

02 Nov 2017

Lupin Q2 profit falls on lower U.S. sales, but beats estimates

Drugmaker Lupin Ltd said on Monday second-quarter net profit fell more than 30 percent, as regulatory scrutiny and pricing pressure in the United States, its biggest market, dampened sales.

30 Oct 2017

UPDATE 1-India's Lupin Q2 profit falls on lower U.S. sales, but beats estimates

* U.S. sales down 32 pct (Recasts, adds details, bullets, share moves)

30 Oct 2017

BRIEF-Lupin says co on track with complex generic pipeline

* Says as expected, co continues to see pricing pressure for its U.S. generic business

30 Oct 2017

India's Lupin Q2 profit down 31 pct, but slightly above consensus

Oct 30 Indian drugmaker Lupin Ltd on Monday said its second-quarter profit fell about 31 percent, but the results were slightly above estimates.

30 Oct 2017

BRIEF-India's Lupin Sept-qtr consol profit down 31 pct

* Sept quarter consol net profit 4.55 billion rupees versus profit of 6.62 billion rupees last year

30 Oct 2017

Earnings vs. Estimates